At a Glance
“Breadth of learning opportunities and skills developed.”
“Flexibility in vacation and WFH policy.”
“Competitive compensation and minimal travel requirements.”
“Hours are unpredictable sometimes…”
“Still growing, so staffing can be strained at times.”
“Current growing pains.”
“Life sciences specialist.”
“Strong reputation in healthcare.”
“Good in pharma space.”
Trinity seamlessly transitioned our entire workforce to work remotely. We continue to recruit and interview candidates for a variety of roles across all divisions and levels through virtual outlets including Skype for Business and Microsoft Teams. As our Executive Team continues to closely monitor the implications of COVID-19, we have prolonged our typical interview processes in some cases so they can continue to make the best business decisions for whole-company health.
We continue to onboard new hires virtually. In regards to internships, we have made the difficult decision to cancel our 2020 Summer Internship Program and will be extending full-time offers to invite these individuals to join Trinity in 2021. At this time, we do not expect to be back in the office to ensure a successful continuation of the high-caliber, successful internship experience we’ve provided over the years.
Trinity remains dedicated to servicing Life Sciences companies during this time and has begun to share some of the insights and data it has collected related to the pandemic. For more information on the thought leadership Trinity is making available, please visit our website and click the COVID-19 Resources tab.
Originally founded in 1996 as TRINITY Partners, TRINITY has since grown to a global team of advisors, technical experts, data integrators and technology innovators. TRINITY is one of the fastest-growing consulting firms in the healthcare industry--its track record of consistent growth for over two decades has been fueled by a commitment to clients, passion for the life sciences, and depth of expertise in the industry. Since the beginning, TRINITY has been evidence-forward in all analyses and recommendations, focused on quality and accuracy first and foremost. Today, having leveraged our thoughtful approach and dedication into a global organization, TRINITY has the client footprint, deep experience, and technology solutions to have a powerful impact on clients’ business, and the industry as a whole.
TRINITY’s approach is focused on its foundation of three: advisory services, insights & analytics, and technology. By seamlessly integrating each of these solutions, TRINITY is able to meet the distinct needs of both emerging biotech firms and established pharmaceutical companies. TRINITY can provide comprehensive end-to-end analytical and strategic support to early-stage companies, as well as tools and solutions for larger, more established life sciences clients. TRINITY’s deep industry expertise, powerful tools, and focus on evidence-based insights have enabled this firm to drive commercialization forward for some of the most innovative therapies and devices in the industry.
While TRINITY is always growing, the core values that have motivated the team for two decades have remained the same. TRINITY bases every relationship with its clients on trust, manifested through a commitment to going beyond what is expected. TRINITY company culture is deeply rooted in a shared passion for healthcare, respect for the life-changing innovations customers pursue, and an innate sense of intellectual curiosity that fuels everything they do.
TRINITY was founded over 20 years ago, in 1996. The firm is led by the Chief Executive Officer, David B. Fitzhenry, who has been with TRINITY for 22 years. Dave graduated from Harvard University, and has a long track record as a consulting leader in the biotech, pharmaceutical, and medical device industries. His clients encompass a wide selection of organizations, including venture-backed startups, mid-cap life sciences organizations, and traditional big pharma and biotech organizations. Under his leadership, the firm's consulting practice has achieved annual growth in excess of 20 percent.
In the News
July 1, 2019
TRINITY Opens First European Office in Munich
TRINITY officially opened its flagship European office in Munich, Germany. The 20-year-old firm, with over 250 professionals working with more than 100 biopharmaceutical and medical device clients annually, will now serve clients from a dedicated European office.
Alexander Fink, Managing Partner Europe, will head TRINITY’s operations in Europe and will oversee strategy and direction in the European markets. Jackson Carroll, Principal, joins his leadership team and will be supported by a team combining European experience both at TRINITY and from other top-tier strategic advisory firms. The European team will be positioned to develop evidence-based solutions for life sciences companies in Europe, leveraging European experience and seamlessly integrating TRINITY’s global knowledge and tools.
June 10, 2019
TRINITY Publishes a White Paper on Reimbursement of Cell and Gene Therapies
TRINITY published a white paper exploring the truth of reimbursement challenges for cell and gene therapies (CGTs). This new white paper explores the truth of reimbursement challenges for CGTs through payer research and economic analysis, highlighting key misconceptions of the unique challenges facing CGTs in reimbursement. Key Insights Include:
- Given current trends in the CGT market (e.g. number of CGTs, prices, target populations), the current reimbursement model is rapidly becoming unsustainable
- Misunderstanding of payers’ needs and situation leading to misguided focus of manufacturers entering this space
- Revolution in reimbursement model is needed if CGT market expansion is significant
June 4, 2019
TRINITY Launches New Corporate Identity, Integrated Platform for the Global Life Sciences Industry
TRINITY Partners, a strategic partner to leading life sciences companies, today announced it has changed its brand identity to TRINITY and launched its new website at TRINITYlifesciences.com. The TRINITY name also highlights the company’s three-part foundation: advisory services, insights & analytics, and technology. By seamlessly integrating its knowledge through an evidence-based platform called “TRINITYEdge,” the company is able to meet the distinct needs of both emerging biotech firms and established pharmaceutical companies.
“TRINITY is a natural evolution of our identity as a firm and an exciting new brand for where we are headed,” said Dave Fitzhenry, Chief Executive Officer of TRINITY
May 16, 2019
TRINITY Attends the 2019 ISPOR Annual Conference
TRINITY is excited to announce that we are attending the ISPOR annual conference May 18th – 22nd in New Orleans. ISPOR is the leading professional society for health economics and outcomes research (HEOR) globally. The Society’s mission is to promote HEOR excellence to improve decision making for health globally. TRINITY has 4 poster presentations this year: two systematic literature reviews, a physician chart audit study, as well as a sequence analysis in Medicare claims predicting a diagnosis of interest. TRINITY is proud to be a part of this exciting discussion.
September 6, 2018
TRINITY Partners to Acquire TGaS Advisors
TRINITY Partners today announced it has acquired TGaS® Advisors, the leading benchmarking and advisory services firm for commercial organizations in the life sciences industry. The acquisition marks another proof point in TRINITY Partners’ overarching growth strategy and builds upon previous successes and momentum including a strengthened leadership team, U.S. and global expansion, and enhanced product offerings.
TGaS Advisors will operate as a wholly-owned division of TRINITY Partners and brings to bear more than 15 years of industry experience including work with a majority of the top 50 pharmaceutical companies and a growing number of biotech companies. Under terms of the agreement, TRINITY will add TGaS’s unique benchmarking products to its real-world evidence and primary market research capabilities to power its strategic advisory offerings in corporate and product strategy, launch readiness, pricing and market access, and health economics. The joint go-to-market offerings will enhance clients’ ability to deliver life changing innovations to patients around the globe.
March 7, 2019
Bloomberg – Baystate Business: Baseball, Business and Boston (Radio)
Dave Fitzhenry, TRINITY’s CEO and Managing Partner, sat down with Bloomberg Baystate Business radio yesterday as their C-Suite guest, to discuss TRINITY’s Annual Drug Index as well as the current state of life sciences, including trends in orphan drugs, oncology and personalized medicine.
230 Third Ave.
Waltham, MA 02451
Phone: (781) 577-6300
Employer Type: Private
Chief Executive Officer: David B. Fitzhenry
2019 Employees (All Locations): 350
Boston, MA (HQ)
New York, NY
San Francisco, CA
- Corporate Strategy & Business Development
- Strategy Product Planning
- Launch Excellence & Brand Planning
- Value & Access
- Evidence & Outcomes
- Commercial Operations
Insights and Analytics
- Commercial Analytics
- Market Research
- Real World Evidence
- Benchmarking, Powered by TGaS Advisors